ANI Pharmaceuticals Reports Full Year and Fourth Quarter 2019 Results, Provides 2020 Guidance and Remains on Track to Submit Cortrophin® Gel sNDA to FDA in March 2020

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. FDX
3. META
4. ABBV
5. SPY
6. IBM
7. NKE
8. MU
9. USO
10. NVDA

Go back to ANI Pharmaceuticals Reports Full Year and Fourth Quarter 2019 Results, Provides 2020 Guidance and Remains on Track to Submit Cortrophin® Gel sNDA to FDA in March 2020

ANI Pharma (ANIP) Misses Q4 EPS by 10c, Revenues Beat; Offers FY20 EPS/Revenue Guidance Below Consensus

February 27, 2020 8:36 AM EST

ANI Pharma (NASDAQ: ANIP) reported Q4 EPS of $1.08, $0.10 worse than the analyst estimate of $1.18. Revenue for the quarter came in at $57.1 million versus the consensus estimate of $51.63 million.

For the fourth quarter 2019:

Net revenues of $48.0 million versus $57.1 million in 2018GAAP net loss of $4.8 million and diluted GAAP loss per share of $0.41Adjusted non-GAAP EBITDA of $17.4 millionAdjusted non-GAAP diluted... More